

## ASX Release

---

# Interviews with Michael Baker

**PERTH, AUSTRALIA – 23 January 2020:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that Dr Michael Baker has been interviewed by Boardroom Media as well as The West Australian newspaper.

Both the interview with Boardroom Media and the article in The West Australian can be found on SUDA's website.

<https://sudapharma.com/investors/media/>

For and on behalf of the Board and for further information please contact:

**Paul Hopper**  
**Executive Chairman**  
**SUDA Pharmaceuticals Ltd**  
Tel: +61 (0) 406 671 515  
phopper@sudapharma.com

**Dr Michael Baker**  
**Chief Executive Officer**  
**SUDA Pharmaceuticals Ltd**  
Tel +61 (0) 403 468 187  
mbaker@sudapharma.com

### NOTES TO EDITORS:

#### About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; pulmonary hypertension; epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)